GSK’s Bepirovirsen for Chronic Hepatitis B Receives FDA Priority Review and Breakthrough Therapy Designation

GSK USA

Overview

GSK announced that its investigational antisense oligonucleotide (ASO), Bepirovirsen, a candidate for chronic Hepatitis B, has been granted both Priority Review and Breakthrough Therapy Designation (BTD) by the U.S. FDA. BTD is awarded to therapies that demonstrate preliminary clinical evidence of substantial improvement over existing treatments for serious conditions, expediting development and review. This dual designation underscores Bepirovirsen’s potential to revolutionize chronic Hepatitis B treatment by targeting viral antigen production.

In Depth

Background

Chronic Hepatitis B is a severe global health issue affecting hundreds of millions worldwide, leading to potentially fatal complications such as cirrhosis, liver failure, and hepatocellular carcinoma. Current treatments aim to suppress viral replication but rarely achieve a complete cure or functional eradication of the virus. Consequently, there is an urgent need for more effective treatments with novel mechanisms of action.

Key Findings / Results

GSK, a major pharmaceutical company, announced that its investigational drug Bepirovirsen, a candidate for chronic Hepatitis B, has received both “Priority Review” and “Breakthrough Therapy Designation (BTD)” from the U.S. Food and Drug Administration (FDA). This dual designation indicates a high likelihood that Bepirovirsen could offer significant benefits to patients.

• Mechanism of Action of Bepirovirsen: Bepirovirsen belongs to an innovative modality known as antisense oligonucleotides (ASOs). ASOs work by binding to specific messenger RNAs (mRNAs), thereby inhibiting the production of proteins essential for viral replication or interfering with critical stages of the viral life cycle. Bepirovirsen specifically targets the production of Hepatitis B surface antigen (HBsAg), aiming to suppress viral activity and restore immune responses.
• Significance of Priority Review and BTD:
  • Priority Review: Granted to drugs for serious conditions that offer significant improvement in safety or effectiveness over existing therapies, leading to a shortened FDA review period compared to standard reviews.
  • Breakthrough Therapy Designation (BTD): Conferred upon therapies for serious conditions that show preliminary clinical evidence of potentially substantial improvement over available therapies. BTD facilitates intensive FDA guidance throughout the development process, accelerating both development and review.
• Clinical Expectation: These designations suggest that Bepirovirsen’s clinical trial data thus far are highly promising and indicate its potential to outperform existing standard-of-care treatments for chronic Hepatitis B patients. Particularly, its approach to functional cure, distinct from conventional antiviral suppression, holds significant promise.

Technical Significance & Outlook

The FDA’s Priority Review and Breakthrough Therapy Designation for Bepirovirsen represent a significant advancement in chronic Hepatitis B treatment. This ASO-based therapy expands the possibility of achieving viral eradication and functional cure, which have been challenging with conventional treatments. The expedited review process means patients could gain access to this innovative therapy sooner. This success reaffirms the versatility and efficacy of the ASO platform and could accelerate research into its application for other chronic viral infections and genetic disorders. For GSK, this marks a substantial strengthening of its pipeline in the infectious disease area and is expected to contribute significantly to global health initiatives. The targeted mRNA degradation approach offers a potent method to reduce circulating viral antigens, potentially enabling immune reconstitution and a sustained virologic response, which is a key technical goal in HBV therapy.